262 related articles for article (PubMed ID: 24124571)
21. FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.
Sullivan PM; Kumar R; Li W; Hoglund V; Wang L; Zhang Y; Shi M; Beak D; Cheuk A; Jensen MC; Khan J; Dimitrov DS; Orentas RJ
Mol Cancer Ther; 2022 Oct; 21(10):1608-1621. PubMed ID: 35877472
[TBL] [Abstract][Full Text] [Related]
22. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.
Futami T; Kawase T; Mori K; Asaumi M; Kihara R; Shindoh N; Kuromitsu S
Sci Rep; 2019 Oct; 9(1):14627. PubMed ID: 31601997
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
[TBL] [Abstract][Full Text] [Related]
25. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
26. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
[TBL] [Abstract][Full Text] [Related]
29. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
30. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.
Liu C; Mu X; Wang X; Zhang C; Zhang L; Yu B; Sun G
Molecules; 2019 Apr; 24(7):. PubMed ID: 30959969
[TBL] [Abstract][Full Text] [Related]
31. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
32. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.
Kwiatkowski BA; Kirillova I; Richard RE; Israeli D; Yablonka-Reuveni Z
J Cell Physiol; 2008 Jun; 215(3):803-17. PubMed ID: 18186042
[TBL] [Abstract][Full Text] [Related]
33. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract][Full Text] [Related]
34. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
35. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
[TBL] [Abstract][Full Text] [Related]
36. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
37. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
38. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
39. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
[No Abstract] [Full Text] [Related]
40. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]